bioRxivNeurosciencePreprint
USP14 regulates pS129 α-synuclein levels and oxidative stress in human SH-SY5Y dopaminergic cells
Vignesh Srinivasan, Rabah SoliymaniiD, Larisa B. IvanovaiD, Ove ErikssoniD, Nina Peitsaro, Maciej M. LalowskiiD, Mati M. KarelsoniD, Dan LindholmiD
Abstract
Ubiquitin specific protease-14 (USP14) is critical for controlling protein homeostasis disturbed in human disorders like Parkinso[n]s disease (PD). Here we investigated the role of USP14 in regulating proteasome and autophagy pathways, and their influence on -synuclein (-syn) degradation. Data showed that -syn and phosphorylated serine129 -syn (pS129 -syn) were elevated in USP14 gene-deleted SH-SY5Y dopaminergic cells with concomitant reduction in proteasome activity. Inhibition of proteasomes using MG132 particularly elevated pS129 -syn in these cells, but the levels were not influenced by inhibiting autophagy using chloroquine. In contrast, autophagy and the CLEAR (Coordinated Lysosomal Expression and Regulation) pathways were elevated in USP14 lacking cells with an upregulation of the transcription factor TFEB. USP14-ablated cells also exhibited increases in reactive oxidative species (ROS) and elongation of mitochondria. The addition of N-Acetylcysteine amide (NACA) to counteract oxidative stress, reduced pS129 -syn and -syn levels in USP14 deficient cells. Phospho-proteomic analyses revealed that USP14 is phosphorylated at S143 affecting its function and structure as shown by molecular modeling, and protein interaction studies. Re-expression of wild-type and the phospho-mimetic S143D-USP14 mutant decreased ROS, pS129 -syn, and -syn in USP14 lacking cells. These results demonstrate that pS129 -syn levels are sensitive to oxidative stress in SH-SY5Y dopaminergic cells. USP14 by stimulating the proteasome activity and reducing oxidative stress is a promising factor for targeting -syn and its pathogenic variants in PD.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
Jean-Louis A. Parmasad, Konrad M. Ricke, … Maxime W.C. Rousseaux·Cell Death and DiseasePeer-reviewed·Apr 4, 2024
- Blm10/PA200-activated 20S proteasomes promote α-synuclein degradation and bypass proteasome inhibition in Parkinson disease models
Tariq Tammam Ali, Anton Zhornyak, … Gerhard H. Braus·Aging CellPeer-reviewed·May 28, 2026
- USP15 REGULATES NEUROINFLAMMATION AND DRIVES PATHOGENESIS IN SYNUCLEINOPATHIES
Nassima Fodil, Esther del Cid‐Pellitero, … Philippe Gros·bioRxiv·Sep 12, 2026
- In vivo Proximity & Spatial Proteomics with CRISPR Screening Identify STXBP1 as a Protective Modifier of a-synuclein Toxicity in Dopamine Neurons.
Daichi Shonai, Julie K. Kent, … Scott H. Soderling·bioRxiv·Jan 17, 2026
- Genetic inactivation of the USP19 deubiquitinase regulates a-synuclein ubiquitination and inhibits accumulation of Lewy body like aggregates in mice
Lenka Schorova, Nathalie Bedard, … Simon S. Wing·bioRxiv·Dec 21, 2022
- Mathematical modeling of the role of α-synuclein and dopamine in cell death in Parkinson’s disease provides the molecular basis to the toxicity of different point mutations
Gourvendu Saxena, Utkarsh Khandelwal, Mukesh Doble·bioRxiv·Jul 25, 2019